(Q30807010)

English

Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 June 2017

Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trial (English)

1 reference

Europe PubMed Central

26 June 2017

0 references

pathophysiology

1 reference

based on heuristic

inferred from title

rheumatoid arthritis

0 references

1 reference

based on heuristic

inferred from title

Xavier Le Loët

11

object named as

Xavier Le Loët

0 references

Maxime Dougados

13

object named as

Maxime Dougados

1 reference

Europe PubMed Central

26 June 2017

12

object named as

Bernard Combe

1 reference

Europe PubMed Central

26 June 2017

Xavier Mariette

14

object named as

Xavier Mariette

1 reference

Europe PubMed Central

26 June 2017

author name string

Jérémie Sellam

1

1 reference

Europe PubMed Central

26 June 2017

Sandrine Marion-Thore

2

1 reference

Europe PubMed Central

26 June 2017

Florent Dumont

3

1 reference

Europe PubMed Central

26 June 2017

Sébastien Jacques

4

1 reference

Europe PubMed Central

26 June 2017

Henri-Jean Garchon

5

1 reference

Europe PubMed Central

26 June 2017

Stéphanie Rouanet

6

1 reference

Europe PubMed Central

26 June 2017

Yassine Taoufik

7

1 reference

Europe PubMed Central

26 June 2017

Houria Hendel-Chavez

8

1 reference

Europe PubMed Central

26 June 2017

Jean Sibilia

9

1 reference

Europe PubMed Central

26 June 2017

Jacques Tebib

10

1 reference

Europe PubMed Central

26 June 2017

Gilles Chiocchia

15

1 reference

Europe PubMed Central

26 June 2017

publication date

1 August 2014

1 reference

Europe PubMed Central

26 June 2017

Arthritis & Rheumatology

1 reference

Europe PubMed Central

26 June 2017

66

1 reference

Europe PubMed Central

26 June 2017

8

1 reference

Europe PubMed Central

26 June 2017

2015-2025

1 reference

Europe PubMed Central

26 June 2017

The problem of choice: current biologic agents and future prospects in RA.

1 reference

https://api.crossref.org/works/10.1002%2FART.38671

21 January 2018

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FART.38671

21 January 2018

Rituximab: a new therapeutic alternative in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.38671

21 January 2018

B lymphocytes induce the formation of follicular dendritic cell clusters in a lymphotoxin alpha-dependent fashion.

1 reference

https://api.crossref.org/works/10.1002%2FART.38671

21 January 2018

Consensus statement on the use of rituximab in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.38671

21 January 2018

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

https://api.crossref.org/works/10.1002%2FART.38671

21 January 2018

Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1002%2FART.38671

21 January 2018

CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1002%2FART.38671

21 January 2018

Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment

1 reference

https://api.crossref.org/works/10.1002%2FART.38671

21 January 2018

Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1002%2FART.38671

21 January 2018

The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1002%2FART.38671

21 January 2018

Identification of candidate genes for rituximab response in rheumatoid arthritis patients by microarray expression profiling in blood cells.

1 reference

https://api.crossref.org/works/10.1002%2FART.38671

21 January 2018

A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1002%2FART.38671

21 January 2018

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.38671

21 January 2018

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

1 reference

https://api.crossref.org/works/10.1002%2FART.38671

21 January 2018

Diagnosis of multiple cancer types by shrunken centroids of gene expression

1 reference

https://api.crossref.org/works/10.1002%2FART.38671

21 January 2018

NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.38671

21 January 2018

Interleukin-33 biology with potential insights into human diseases

1 reference

https://api.crossref.org/works/10.1002%2FART.38671

21 January 2018

Loss of Tolerance and Autoimmunity Affecting Multiple Organs inSTAT5A/5B-Deficient Mice

1 reference

https://api.crossref.org/works/10.1002%2FART.38671

21 January 2018

Analysis of CD97 expression and manipulation: antibody treatment but not gene targeting curtails granulocyte migration

1 reference

https://api.crossref.org/works/10.1002%2FART.38671

21 January 2018

Identification of tripartite motif-containing 22 (TRIM22) as a novel NF-κB activator

1 reference

https://api.crossref.org/works/10.1002%2FART.38671

21 January 2018

Expression of receptor tyrosine kinase Axl and its ligand Gas6 in rheumatoid arthritis: evidence for a novel endothelial cell survival pathway

1 reference

https://api.crossref.org/works/10.1002%2FART.38671

21 January 2018

Importance of correlation between gene expression levels: application to the type I interferon signature in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.38671

21 January 2018

Identifiers

10.1002/ART.38671

1 reference

Europe PubMed Central

26 June 2017

1 reference

Europe PubMed Central

26 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30807010&oldid=1561086670"